South American Real Estate News

Argentina will receive some 22 million doses of AstraZeneca vaccines

Post available in: English

Argentina has struck a deal with drug maker AstraZeneca Plc to receive around 22 million doses of its COVID-19 vaccine being developed with the University of Oxford, with the aim to start deliveries in the first half of next year.

 The drug maker, one of a number developing vaccines worldwide to fight the novel coronavirus, said in a statement circulated by the government on Saturday that the delivery time-frame depended on ongoing trials being successful and obtaining necessary approvals by regulatory authorities.

Argentina, which is starting to see new cases slow, is hoping to receive some 10 million doses of Russia’s Sputnik V vaccine and a smaller number of doses of Pfizer Inc’s vaccine between December-January.

Argentina is among the world’s hardest hit countries, despite imposing a strict lockdown back in March. It has logged 1.23 million cases of the disease and 33,136 deaths.

Regulators have yet to approve a vaccine for COVID-19 but large global trials are well underway and early results are expected in November and December. Argentina is helping to produce the AstraZeneca-Oxford vaccine for Latin America.

Source: Mercopress

(Visited 141 times, 1 visits today)

About Gateway to South America

Gateway to South America was established in 2006 as a single office in Buenos Aires. The company has since expanded into a vibrant regional network, servicing the Southern Cone clients in Argentina, Brazil, Chile, Paraguay, Peru and Uruguay with professional real estate marketing services. If you enjoy reading our news site please share it on your social media below.

Post available in: English

0 POST COMMENT

Comments from our readers

Visit us on LinkedInVisit us on FacebookVisit us on TwitterVisit us on PinterestCheck our RSS Feed